Godavari Biorefineries Limited has informed the Exchange about Transcript
GODAVARIB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Biorefineries reported Q3 FY26 total income of INR461.9 crores (up 2.5% YoY) with EBITDA growing 13.8% YoY to INR45.1 crores and EBITDA margin expanding 97 basis points to 9.8%. Profit before tax (before exceptional items) jumped 152% YoY to INR21.4 crores, supported by a 48% YoY decline in finance costs. The bio-based chemicals segment saw EBITDA margin rise to 7.7% from 4.5% a year ago, with specialty chemicals making up 62% of the chemical basket in 9M FY26. Management reiterated a 3x EBITDA target by FY29 with a capex plan of INR325 crores (75% for bio-based chemicals, 25% for ethanol). Other highlights included a US patent for a triple-negative breast cancer molecule, the formation of US subsidiary Sathgen Therapeutics, an MOU with Synthomer for bio-based butyl acrylate, and the Jivana consumer brand crossing INR100 crores in 9M revenue across 7,500+ outlets.
Strong margin expansion, falling finance costs, and a clear multi-year growth roadmap are positives for shareholders. However, ethanol segment margin pressure from rising cane costs and frozen government pricing, plus a delay in commissioning the grain-based distillery, are near-term watch points.